Most of the letters dealt with several FDA regulatory violations by pharma companies or their agents. The violations were cited for both digital and traditional communications. The paper tries to get a handle on the regulatory ...
|
|
Scooped by
Lionel Reichardt / le Pharmageek
April 4, 2013 12:39 PM
|
No comment yet.
Sign up to comment
Your new post is loading...